Sarah Gaffey

2.8k total citations
22 papers, 402 citations indexed

About

Sarah Gaffey is a scholar working on Genetics, Molecular Biology and Cancer Research. According to data from OpenAlex, Sarah Gaffey has authored 22 papers receiving a total of 402 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Genetics, 11 papers in Molecular Biology and 11 papers in Cancer Research. Recurrent topics in Sarah Gaffey's work include Glioma Diagnosis and Treatment (16 papers), Histone Deacetylase Inhibitors Research (8 papers) and Cancer, Hypoxia, and Metabolism (6 papers). Sarah Gaffey is often cited by papers focused on Glioma Diagnosis and Treatment (16 papers), Histone Deacetylase Inhibitors Research (8 papers) and Cancer, Hypoxia, and Metabolism (6 papers). Sarah Gaffey collaborates with scholars based in United States and Switzerland. Sarah Gaffey's co-authors include David A. Reardon, Patrick Y. Wen, Alona Muzikansky, Eudocia Q. Lee, Andrew D. Norden, Katrina H. Smith, Christine McCluskey, Keith L. Ligon, Tracy T. Batchelor and Howard Colman and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Clinical Cancer Research.

In The Last Decade

Sarah Gaffey

21 papers receiving 398 citations

Peers

Countries citing papers authored by Sarah Gaffey

Since Specialization

Citations

This map shows the geographic impact of Sarah Gaffey's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sarah Gaffey with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sarah Gaffey more than expected).

Fields of papers citing papers by Sarah Gaffey

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sarah Gaffey. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sarah Gaffey. The network helps show where Sarah Gaffey may publish in the future.

Co-authorship network of co-authors of Sarah Gaffey

This figure shows the co-authorship network connecting the top 25 collaborators of Sarah Gaffey. A scholar is included among the top collaborators of Sarah Gaffey based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sarah Gaffey. Sarah Gaffey is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Real-world enrollment for a prospective clinico-genomic database using a pragmatic technology-enabled platform 2025 ·Contemporary Clinical Trials Communications ·(unknown), Ariel B. Bourla, (unknown), Katja Schulze, Sophia L. Maund, Yi Cao, (unknown), Elizabeth H. Williams, Sarah Gaffey, Richard Zuniga, (unknown), Vladan Antic, Michelle Y. Doral, (unknown), Neal J. Meropol, Anne C. Chiang	1
2	TCF-001 TRACK (Target Rare Cancer Knowledge): A national patient-centric precision oncology trial for rare cancers. 2021 ·Journal of Clinical Oncology ·Vivek Subbiah, Roman Groisberg, (unknown), James M. Cleary, Ishwaria M. Subbiah, (unknown), Mary E. Oster, (unknown), Julia A. Elvin, Jason K. Sicklick, Sarah Gaffey, (unknown), Brian M. Alexander, J. Jack Lee, Pradip De, Shumei Kato, Razelle Kurzrock	4
3	Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT): A Bayesian Adaptive Platform Trial to Develop Precision Medicines for Patients With Glioblastoma 2019 ·JCO Precision Oncology ·Brian M. Alexander, Lorenzo Trippa, Sarah Gaffey, Isabel Arrillaga‐Romany, Eudocia Q. Lee, Mikael L. Rinne, Manmeet S. Ahluwalia, Howard Colman, Geoffrey Fell, Evanthia Galanis, John de Groot, Jan Drappatz, Andrew B. Lassman, David M. Meredith, Burt Nabors, Sandro Santagata, David Schiff, Mary Welch, Keith L. Ligon, Patrick Y. Wen	51
4	Phase II trial of ponatinib in patients with bevacizumab‐refractory glioblastoma 2019 ·Cancer Medicine ·Eudocia Q. Lee, Alona Muzikansky, Dan G. Duda, Sarah Gaffey, Jörg Dietrich, Lakshmi Nayak, Ugonma Chukwueke, Rameen Beroukhim, Lisa Doherty, (unknown), Debra C. LaFrankie, (unknown), (unknown), Sandra Ruland, (unknown), Jennifer L. Bruno, Keith L. Ligon, David A. Reardon, Patrick Y. Wen	29
5	ATIM-12. NEOADJUVANT ANTI-PD-1 IMMUNOTHERAPY PROMOTES INTRATUMORAL AND SYSTEMIC IMMUNE RESPONSES IN RECURRENT GLIOBLASTOMA: AN IVY CONSORTIUM TRIAL 2018 ·Neuro-Oncology ·Robert M. Prins, Aaron Mochizuki, Joey Orpilla, Alexander Lee, Tom B. Davidson, Sarah Gaffey, Catherine Sanders, Julie Rytlewski, Benjamin M. Ellingson, Gang Li, William H. Yong, Jennifer Clarke, Isabel Arrillaga‐Romany, Howard Colman, David A. Reardon, Thomas Kaley, John de Groot, Linda M. Liau, Patrick Y. Wen, Timothy F. Cloughesy	1
6	Phase I and Biomarker Study of Plerixafor and Bevacizumab in Recurrent High-Grade Glioma 2018 ·Clinical Cancer Research ·Eudocia Q. Lee, Dan G. Duda, Alona Muzikansky, Elizabeth R. Gerstner, John G. Kuhn, David A. Reardon, Lakshmi Nayak, Andrew D. Norden, Lisa Doherty, Debra C. LaFrankie, (unknown), Trupti D. Vardam, Katrina H. Smith, Christine McCluskey, Sarah Gaffey, Tracy T. Batchelor, Rakesh K. Jain, Patrick Y. Wen	49
7	ALLELE: A consortium for prospective genomics and functional diagnostics to guide patient care and trial analysis in newly-diagnosed glioblastoma. 2018 ·Journal of Clinical Oncology ·Mehdi Touat, Adrian M. Dubuc, David M. Meredith, Sarah Gaffey, (unknown), Shakti Ramkissoon, John Frederick De Groot, Evanthia Galanis, Mary Welch, Burt Nabors, Isabel Arrillaga, E. Antonio Chiocca, Sandro Santagata, David Schiff, Manmeet S. Ahluwalia, Howard Colman, Jan Drappatz, Brian M. Alexander, Patrick Y. Wen, Keith L. Ligon	0
8	Phase II trial of ponatinib in patients with bevacizumab-refractory glioblastoma. 2018 ·Journal of Clinical Oncology ·Eudocia Q. Lee, Alona Muzikansky, David A. Reardon, Jörg Dietrich, Lakshmi Nayak, Dan G. Duda, Ugonma Chukwueke, Rameen Beroukhim, Lisa Doherty, (unknown), Debra C. LaFrankie, (unknown), (unknown), Sandra Ruland, (unknown), Jennifer L. Bruno, Sarah Gaffey, Patrick Y. Wen	5
9	Phase II study of pembrolizumab or pembrolizumab plus bevacizumab for recurrent glioblastoma (rGBM) patients. 2018 ·Journal of Clinical Oncology ·David A. Reardon, Lakshmi Nayak, Katherine B. Peters, Jennifer Clarke, Justin T. Jordan, John Frederick De Groot, Phioanh L. Nghiemphu, Thomas Kaley, Howard Colman, Sarah Gaffey, (unknown), (unknown), (unknown), Annette M. Molinaro, Timothy R. Smith, Mariano Severgnini, Patrick Y. Wen	47
10	Phase 2 and biomarker study of trebananib, an angiopoietin‐blocking peptibody, with and without bevacizumab for patients with recurrent glioblastoma 2017 ·Cancer ·David A. Reardon, Andrew B. Lassman, David Schiff, (unknown), Elizabeth R. Gerstner, Timothy F. Cloughesy, Eudocia Q. Lee, Sarah Gaffey, (unknown), Jennifer L. Bruno, Alona Muzikansky, (unknown), Rakesh K. Jain, Patrick Y. Wen	32
11	Individualized screening trial of innovative glioblastoma therapy (INSIGhT). 2017 ·Journal of Clinical Oncology ·Brian M. Alexander, Lorenzo Trippa, Sarah Gaffey, Isabel Arrillaga, Eudocia Q. Lee, Shyam Tanguturi, Manmeet S. Ahluwalia, Howard Colman, Evanthia Galanis, John Frederick De Groot, Jan Drappatz, Andrew B. Lassman, Burt Nabors, David A. Reardon, David Schiff, Mary Welch, Keith L. Ligon, Patrick Y. Wen	11
12	Safety of pembrolizumab in combination with bevacizumab in recurrent glioblastoma (rGBM). 2016 ·Journal of Clinical Oncology ·David A. Reardon, John Frederick De Groot, Howard Colman, Justin T. Jordan, Mariza Daras, Jennifer Clarke, Phioanh L. Nghiemphu, Sarah Gaffey, Katherine B. Peters	31
13	A phase I study of MLN0128 and bevacizumab in patients with recurrent glioblastoma and other solid tumors. 2016 ·Journal of Clinical Oncology ·Lakshmi Nayak, John L. Hays, Alona Muzikansky, Sarah Gaffey, (unknown), Vinay K. Puduvalli, Eudocia Q. Lee, Mikael L. Rinne, Andrew D. Norden, Rameen Beroukhim, Patrick Y. Wen, L. Austin Doyle, Helen X. Chen, Geoffrey I. Shapiro, David A. Reardon	2
14	Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma 2015 ·Neuro-Oncology ·E. Q. Lee, David A. Reardon, D. Schiff, (unknown), Alona Muzikansky, Sean Grimm, Andrew D. Norden, (unknown), (unknown), Mikael L. Rinne, A. S., Tracy T. Batchelor, (unknown), Christine McCluskey, Katrina H. Smith, Sarah Gaffey, (unknown), Keith L. Ligon, Jeffrey J. Raizer, Patrick Y Wen	103
15	Phase I study of plerixafor and bevacizumab in recurrent high-grade glioma. 2015 ·Journal of Clinical Oncology ·Eudocia Q. Lee, Alona Muzikansky, Elizabeth R. Gerstner, John G. Kuhn, David A. Reardon, Lakshmi Nayak, Andrew D. Norden, Lisa Doherty, (unknown), Debra C. LaFrankie, (unknown), (unknown), (unknown), Katrina H. Smith, Christine McCluskey, Sarah Gaffey, (unknown), Dan G. Duda, Rakesh K. Jain, Patrick Y. Wen	2
16	Phase I study of plerixafor and bevacizumab in recurrent high-grade glioma. 2014 ·Journal of Clinical Oncology ·Katrina H. Smith, Eudocia Q. Lee, Alona Muzikansky, Elizabeth R. Gerstner, Dan G. Duda, David A. Reardon, Lakshmi Nayak, Andrew D. Norden, Lisa Doherty, (unknown), Debra C. LaFrankie, Sandra Ruland, (unknown), (unknown), (unknown), Christine McCluskey, Sarah Gaffey, (unknown), Rakesh K. Jain, Patrick Y. Wen	1
17	Phase II trial of triple tyrosine kinase receptor inhibitor nintedanib in recurrent high-grade gliomas: Final results. 2014 ·Journal of Clinical Oncology ·Andrew D. Norden, David Schiff, Manmeet S. Ahluwalia, Glenn J. Lesser, Lakshmi Nayak, Eudocia Q. Lee, Mikael L. Rinne, Alona Muzikansky, Jörg Dietrich, Benjamin Purow, Katrina H. Smith, Sarah Gaffey, Christine McCluskey, Keith L. Ligon, David A. Reardon, Patrick Y. Wen	1
18	A randomized, placebo-controlled pilot trial of armodafinil for fatigue in patients with gliomas undergoing radiotherapy. 2014 ·Journal of Clinical Oncology ·Eudocia Q. Lee, Alona Muzikansky, Santosh Kesari, Eric T. Wong, Camilo E. Fadul, David A. Reardon, Andrew D. Norden, Lakshmi Nayak, Mikael L. Rinne, Brian M. Alexander, Nils D. Arvold, Lisa Doherty, Debra C. LaFrankie, (unknown), Katrina H. Smith, Sarah Gaffey, Samantha N. Hammond, Jan Drappatz, Patrick Y. Wen	4
19	Interim analysis of a phase I/II study of panobinostat in combination with bevacizumab for recurrent glioblastoma. 2013 ·Journal of Clinical Oncology ·Eudocia Q. Lee, David A. Reardon, David Schiff, Jan Drappatz, Alona Muzikansky, Samantha N. Hammond, Sean Grimm, Andrew D. Norden, Rameen Beroukhim, Christine McCluskey, S. Andrew, Tracy T. Batchelor, Katrina H. Smith, Sarah Gaffey, Mary Gerard, Susan Snodgrass, Jeffrey J. Raizer, Patrick Y. Wen	21
20	Phase II trial of triple-receptor tyrosine kinase receptor inhibitor nintedanib (BIBF 1120) in recurrent high-grade gliomas. 2013 ·Journal of Clinical Oncology ·Andrew D. Norden, David Schiff, Manmeet S. Ahluwalia, Glenn J. Lesser, Lakshmi Nayak, Eudocia Q. Lee, Alona Muzikansky, Jörg Dietrich, Katrina H. Smith, Sarah Gaffey, Christine McCluskey, Keith L. Ligon, David A. Reardon, Patrick Y. Wen	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact